{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:26:21Z","timestamp":1789007181534,"version":"build-2803163510"},"reference-count":35,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Center for Psychedelic Drug Research and Education","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-traumatic stress disorder (PTSD) but has yet to be tested specifically in this condition. Furthermore, current pharmacological and psychotherapeutic treatments for PTSD are difficult to tolerate and limited in efficacy, especially in the US Military Veteran (USMV) population. This open-label pilot study will examine the safety and efficacy of two psilocybin administration sessions (15 mg and 25 mg), combined with psychotherapy, among USMVs with severe, treatment resistant PTSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We will recruit 15 USMVs with severe, treatment resistant PTSD. Participants will receive one low dose (15 mg) and one moderate\/high dose (25 mg) of psilocybin in conjunction with preparatory and post-psilocybin therapy sessions. The primary safety outcome will be the type, severity and frequency of adverse events and suicidal ideation\/behaviour, as measured by the Columbia Suicide Severity Rating Scale. The primary outcome measure for PTSD will be the Clinician Administered PTSD Scale-5. The primary endpoint will be 1 month following the second psilocybin administration session, and the total follow-up time will be 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>All participants will be required to provide written informed consent. The trial has been authorised by the Ohio State University Institutional Review Board (study number: 2022H0280). Dissemination of results will occur via a peer-reviewed publication and other relevant media.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05554094\">NCT05554094<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-068884","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T11:07:43Z","timestamp":1683198463000},"page":"e068884","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05554094","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-8893","authenticated-orcid":false,"given":"Alan K","family":"Davis","sequence":"first","affiliation":[{"name":"Center for Psychedelic Drug Research and Education, The Ohio State University College of Social Work, Columbus, Ohio, USA"},{"name":"Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland, USA"},{"name":"The Ohio State University College of Medicine, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam W","family":"Levin","sequence":"additional","affiliation":[{"name":"Center for Psychedelic Drug Research and Education, The Ohio State University College of Social Work, Columbus, Ohio, USA"},{"name":"The Ohio State University College of Medicine, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-3116","authenticated-orcid":false,"given":"Paul B","family":"Nagib","sequence":"additional","affiliation":[{"name":"Center for Psychedelic Drug Research and Education, The Ohio State University College of Social Work, Columbus, Ohio, USA"},{"name":"The Ohio State University College of Medicine, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey B","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Center for Psychedelic Drug Research and Education, The Ohio State University College of Social Work, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaelle L","family":"Lancelotta","sequence":"additional","affiliation":[{"name":"Center for Psychedelic Drug Research and Education, The Ohio State University College of Social Work, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"2025120617593354000_13.5.e068884.1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2025120617593354000_13.5.e068884.2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"2025120617593354000_13.5.e068884.3","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"2025120617593354000_13.5.e068884.4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110"},{"key":"2025120617593354000_13.5.e068884.5","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114565144"},{"key":"2025120617593354000_13.5.e068884.6","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296"},{"key":"2025120617593354000_13.5.e068884.7","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2016.1170135"},{"key":"2025120617593354000_13.5.e068884.8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31887\/DCNS.2015.17.2\/jflory","article-title":"Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations","volume":"17","author":"Flory","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"key":"2025120617593354000_13.5.e068884.9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09540261.2021.1919062","article-title":"Psilocybin and MDMA for the treatment of trauma-related psychopathology","volume":"33","author":"Bird","year":"2021","journal-title":"Int Rev Psychiatry"},{"key":"2025120617593354000_13.5.e068884.10","doi-asserted-by":"crossref","first-page":"100538","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025120617593354000_13.5.e068884.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-011-0442-0"},{"key":"2025120617593354000_13.5.e068884.12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.55460\/663M-6L7P","article-title":"Special operations forces and incidence of post-traumatic stress disorder symptoms","volume":"12","author":"Hing","year":"2012","journal-title":"J Spec Oper Med"},{"key":"2025120617593354000_13.5.e068884.13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.55460\/BQES-AM8H","article-title":"Resilience and suicide in special operations forces: state of the science via integrative review","volume":"19","author":"Rocklein Kemplin","year":"2019","journal-title":"J Spec Oper Med"},{"key":"2025120617593354000_13.5.e068884.14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41380-021-01423-4","article-title":"Predicting suicide attempts among U.S. Army soldiers after leaving active duty using information available before leaving active duty: results from the study to assess risk and resilience in servicemembers-longitudinal study (starrs-ls)","volume":"27","author":"Stanley","year":"2022","journal-title":"Mol Psychiatry"},{"key":"2025120617593354000_13.5.e068884.15","doi-asserted-by":"crossref","unstructured":"Holliday R , Borges LM , Stearns-Yoder KA , et al . Posttraumatic stress disorder, suicidal ideation, and suicidal self-directed violence among U.S. military personnel and veterans: a systematic review of the literature from 2010 to 2018. Front Psychol 2020;11. doi:10.3389\/fpsyg.2020.01998 Available: https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyg.2020.01998","DOI":"10.3389\/fpsyg.2020.01998"},{"key":"2025120617593354000_13.5.e068884.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18645-3","article-title":"Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality","volume":"12","author":"Jones","year":"2022","journal-title":"Sci Rep"},{"key":"2025120617593354000_13.5.e068884.17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/02698811211058923","article-title":"MDMA\/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults","volume":"36","author":"Jones","year":"2022","journal-title":"J Psychopharmacol"},{"key":"2025120617593354000_13.5.e068884.18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2025120617593354000_13.5.e068884.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2009.03.037"},{"key":"2025120617593354000_13.5.e068884.20","doi-asserted-by":"crossref","unstructured":"Watkins LE , Sprang KR , Rothbaum BO . Treating PTSD: a review of evidence-based psychotherapy interventions. Front Behav Neurosci 2018;12. doi:10.3389\/fnbeh.2018.00258 Available: https:\/\/www.frontiersin.org\/articles\/10.3389\/fnbeh.2018.00258\/full","DOI":"10.3389\/fnbeh.2018.00258"},{"key":"2025120617593354000_13.5.e068884.21","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009076231175"},{"key":"2025120617593354000_13.5.e068884.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.03.007"},{"key":"2025120617593354000_13.5.e068884.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.8370"},{"key":"2025120617593354000_13.5.e068884.24","unstructured":"van der Kolk BA . The body keeps the score: brain, mind, and body in the healing of trauma. New York, NY, US: Viking, 2014: 443."},{"key":"2025120617593354000_13.5.e068884.25","unstructured":"VA\/DOD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. 2017:200."},{"key":"2025120617593354000_13.5.e068884.26","doi-asserted-by":"crossref","unstructured":"Wisco BE , Nomamiukor FO , Marx BP , et al . Posttraumatic stress disorder in US military veterans: results from the 2019-2020 National health and resilience in veterans study. J Clin Psychiatry 2022;83. doi:10.4088\/JCP.20m14029","DOI":"10.4088\/JCP.20m14029"},{"key":"2025120617593354000_13.5.e068884.27","doi-asserted-by":"crossref","unstructured":"Davis AK , Averill LA , Sepeda ND , et al . Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans. Chronic Stress (Thousand Oaks) 2020;4. doi:10.1177\/2470547020939564","DOI":"10.1177\/2470547020939564"},{"key":"2025120617593354000_13.5.e068884.28","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"2025120617593354000_13.5.e068884.29","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115609019"},{"key":"2025120617593354000_13.5.e068884.30","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111420188"},{"key":"2025120617593354000_13.5.e068884.31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0269881120967878","article-title":"Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD","volume":"35","author":"Davis","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2025120617593354000_13.5.e068884.32","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116678781"},{"key":"2025120617593354000_13.5.e068884.33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"2025120617593354000_13.5.e068884.34","doi-asserted-by":"publisher","DOI":"10.1037\/pas0000486"},{"key":"2025120617593354000_13.5.e068884.35","doi-asserted-by":"publisher","DOI":"10.1037\/pas0000254"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-068884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T01:59:47Z","timestamp":1765072787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-068884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,4]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-068884"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-068884","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}